Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan(University of Minnesota), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Cora N. Sternberg(Cornell University), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Université de Lille), Paul de Souza(St. George Hospital), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Youn C. Park(Janssen (United States)), Fred Saad(Centre Hospitalier de l’Université de Montréal), Thian Kheoh(Janssen (United States)), Peter De Porre(Janssen (Belgium)), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Vahid Naini(Janssen (Belgium)), Thomas W. Flaig(University of Colorado Denver), Neal D. Shore(Carolina Urologic Research Center), Jinhui Li(Stanford University), Matthew R. Smith(Harvard University), Margaret K. Yu(Boston Biomedical (United States)), Peter F.A. Mulders(Radboud University Nijmegen), Arturo Molina(Janssen (United States)), Kurt Miller(Charité - Universitätsmedizin Berlin), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Celestia S. Higano(University of British Columbia), Thomas W. Griffin(Janssen (Belgium)), Joan Carles(Vall d'Hebron Hospital Universitari)
Cited by 1,350
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k